Linda Gowing

Linda Gowing

Auto-generated profile, based on publicly available information

Linda Gowing

University of Adelaide

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2018 in Addiction
Verified
Journal Article
Open access
PDF file
APAmy Peacock
Amy Peacock
Janni LeungJanni Leung
Janni Leung
SLSarah Larney
Sarah Larney
SCSamantha Colledge
Samantha Colledge
MHMatthew Hickman
Matthew Hickman
LDLouisa Degenhardt
Louisa Degenhardt
Aims: This review provides an up‐to‐date curated source of information on alcohol, tobacco and illicit drug use and their associated mortality and burden of disease. Limitations in the data are also discussed, including how these can be addressed in the future.Methods: Online data sources were identified through expert review. Data were obtained mainly from the World Health Organization, United Nations Office on Drugs and Crime and Institute for Health Metrics and Evaluation.Results: In 2015, the estimated prevalence among the adult population was 18.4% for heavy episodic alcohol use (in the past 30 days); 15.2% for daily tobacco smoking; and 3.8, 0.77, 0.37 and 0.35% for past‐year cannabis, amphetamine, opioid and cocaine use, respectively. European regions had the highest prevalence of heavy episodic alcohol use and daily tobacco use. The age‐standardized prevalence of alcohol dependence was 843.2 per 100 000 people; for cannabis, opioids, amphetamines and cocaine dependence it was 259.3, 220.4, 86.0 and 52.5 per 100 000 people, respectively. High‐income North America region had among the highest rates of cannabis, opioid and cocaine dependence. Attributable disability‐adjusted life‐years (DALYs) were highest for tobacco smoking (170.9 million DALYs), followed by alcohol (85.0 million) and illicit drugs (27.8 million). Substance‐attributable mortality rates were highest for tobacco smoking (110.7 deaths per 100 000 people), followed by alcohol and illicit drugs (33.0 and 6.9 deaths per 100 000 people, respectively). Attributable age‐standardized mortality rates and DALYs for alcohol and illicit drugs were highest in eastern Europe; attributable age‐standardized tobacco mortality rates and DALYs were highest in Oceania.Conclusions: In 2015 alcohol use and tobacco smoking use between them cost the human population more than a quarter of a billion disability‐adjusted life years, with illicit drugs costing further tens of millions. Europeans suffered proportionately more, but in absolute terms the mortality rate was greatest in low‐ and middle‐income countries with large populations and where the quality of data was more limited. Better standardized and rigorous methods for data collection, collation and reporting are needed to assess more accurately the geographical and temporal trends in substance use and its disease burden.

11 May 2015 in Addiction
Verified
Journal Article
Closed access
PDF file
LGLinda R. Gowing
Linda R. Gowing
RARobert L. Ali
Robert L. Ali
SASteve Allsop
Steve Allsop
JMJohn Marsden
John Marsden
ETElizabeth E. Turf
Elizabeth E. Turf
JWJohn Witton
John Witton

10 August 2011 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
LGLinda Gowing
Linda Gowing
MFMichael F Farrell
Michael F Farrell
RBReinhard Bornemann
Reinhard Bornemann
LSLynn E Sullivan
Lynn E Sullivan
RARobert Ali
Robert Ali

5 May 2016 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
PGPeter J Gates
Peter J Gates
PSPamela Sabioni
Pamela Sabioni
JCJan Copeland
Jan Copeland
Bernard Le FollBernard Le Foll
Bernard Le Foll
LGLinda Gowing
Linda Gowing

9 May 2016 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
SNSuzanne Nielsen
Suzanne Nielsen
BLBriony Larance
Briony Larance
LDLouisa Degenhardt
Louisa Degenhardt
LGLinda Gowing
Linda Gowing
CKChyanne Kehler
Chyanne Kehler
NLNicholas Lintzeris
Nicholas Lintzeris

1 March 2002 in Drug and Alcohol Review
Verified
Journal Article
Closed access
PDF file
LGLinda R. Gowing
Linda R. Gowing
SHSusan M. Henry‐Edwards
Susan M. Henry‐Edwards
RIRodney J. Irvine
Rodney J. Irvine
RARobert L. Ali
Robert L. Ali
Ecstasy (3,4‐methylenedioxymethamphetamine, MDMA) is the third most used illicit drug, after cannabis and amphetamines. There has been considerable interest in the adverse effects of use, with particular attention given to a small number of deaths related to ecstasy use, and the neurotoxic effects of MDMA. This paper reviews case reports of adverse effects attributed to ecstasy use, and the findings of animal and human studies, so as to identify the health effects of ecstasy use, and factors contributing to their occurrence. The incidence of serious acute adverse events related to ecstasy is low. It is the unpredictability of those adverse events and the risk of mortality and substantial morbidity that makes the health consequences of ecstasy significant. Hyperthermia and hyponatraemia are the most significant acute adverse effects, and can occur even when MDMA is the only drug used. Ecstasy users should be aware of the importance of controlling body temperature and fluid intake, early signs of adverse effects, and the need to seek medical assistance promptly. Neurotoxicity is potentially the most significant long‐term effect of ecstasy. The clinical implications of neurotoxicity are uncertain at this time, but short‐term memory impairment may be significant.